Edition:
United States

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

15.99USD
3:59pm EST
Change (% chg)

$0.52 (+3.36%)
Prev Close
$15.47
Open
$15.42
Day's High
$16.14
Day's Low
$15.30
Volume
635,615
Avg. Vol
845,409
52-wk High
$17.23
52-wk Low
$3.85

Select another date:

Thu, Jan 11 2018

BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer

* IMMUNOMEDICS ANNOUNCES AGREEMENT WITH UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER TO EXPAND SACITUZUMAB GOVITECAN (IMMU-132) INTO PROSTATE CANCER

BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln

* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION

BRIEF-Immunomedics appoints Michael Pehl president and CEO

* Immunomedics appoints Michael Pehl president and chief executive officer to lead next phase of transformative growth

BRIEF-Immunomedics announces first quarter fiscal results

* Immunomedics announces first quarter fiscal 2018 results and provides corporate update

BRIEF-Immunomedics to exchange about $80 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

* Immunomedics announces agreements to exchange approximately $80.0 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

BRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i

* Immunomedics presents interim phase 2 results with sacituzumab govitecan (immu-132) in patients with pretreated metastatic urothelial cancer Source text for Eikon: Further company coverage:

BRIEF-Immunomedics announces publication of cancer drug data

* Immunomedics announces publication of phase 2 results with labetuzumab govitecan (immu-130) that demonstrate promising efficacy as a single agent in patients with metastatic colorectal cancer

BRIEF-Immunomedics reports Q4 loss per share $0.48

* Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline

BRIEF-Immunomedics files for offering of 34.8 mln shares of common stock by selling stockholders

* Immunomedics files for offering of 34.8 million shares of common stock by selling stockholders - sec filing

BRIEF-Immunomedics files for 34.8 mln shares of co's common stock

* Files for 34.8 million shares of co's common stock by the selling stockholders - sec filing

Select another date: